Not all lines are the same

For lines driven chiefly by selected muscle movement, a clinician may discuss a prescription-only botulinum-toxin treatment. Evidence shows a temporary reduction in wrinkle severity in studied facial areas; it is not a treatment for replacing lost volume or rebuilding all aspects of skin structure.

A movement-focused injectable is not a universal answer to every line. Published trials differed in dose, injection area and outcome measures; effects were temporary, and adverse effects including eyelid droop were reported in studies of glabellar lines.

Dermal filler is a different tool from a movement-focused injectable. It places material in selected tissue planes to alter local support, contour or volume; it does not selectively reduce muscle movement.

“Skin booster” is a broad, product-dependent term. The clinic describes this option as targeting hydration, softness and surface quality rather than structural change. Evidence for injectable hyaluronic-acid formulations concerns skin-quality measures such as hydration, texture, radiance, firmness and elasticity.

Evidence for injectable hyaluronic-acid skin-quality treatments is promising, but it is not definitive. Formulations, combinations and study methods vary, and larger randomised trials are still needed; a result cannot be assumed from the category name alone.

Skin boosters remain injection procedures. Redness, swelling, bruising and tenderness may occur, and the same consultation should cover product-specific risks, anatomy, technique and what to do if there is a complication.

A clinically selected home-skincare plan can support barrier care, address some surface concerns and include photoprotection. It is not equivalent to an injectable treatment: skincare cannot replace lost volume or selectively reduce muscle activity. Skincare must be specific to the concern and tolerated by the individual. Some active ingredients can irritate; retinoids, for example, can be unsuitable in pregnancy and may aggravate dryness, redness or inflammation. A product plan should not be presented as universal.

Public education may discuss the clinical category of prescription-only botulinum-toxin treatment neutrally, but must not name or advertise a prescription-only medicine to the general public. Public calls to action should lead to consultation, enquiry or editorial education rather than a named prescription-medicine offer.

Where a clinic treatment page is referenced in this episode, use it only as contextual evidence of the service offered. Do not use clinic copy alone as proof of efficacy, safety, collagen stimulation, fixed duration, prevention or suitability.

• Movement, support or volume, surface quality and barrier care are different clinical contexts.
• Skin-quality evidence is promising, but not definitive.

Evidence note: Evidence and expected effects differ between movement-focused treatment, filler, injectable skin-quality treatments and skincare. Category names alone do not determine an individual result. ^{E04, E05, E06, E08, E12, E13, E16, E17, X04, X07, X08, X13, X14}